Novartis Stops Breast Cancer Study Early Following Positive Results

Novartis halted a Phase 3 trial early for a breast cancer candidate after meeting its primary endpoint of clinically meaningful improvement.

The candidate treatment, in combination with letrozole, was found to significantly extend progression-free survival when compared to letrozole alone, the Swiss drug giant says.